INT243382

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 18
Disease Relevance 14.65
Pain Relevance 0.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

structural molecule activity (CSTA) nucleus (CSTA) intracellular (CSTA)
protein binding, bridging (CSTA) cytoplasm (CSTA)
Anatomy Link Frequency
plasma 4
CSF 2
kidney 1
CSTA (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 44 76.88 Quite High
Migraine 15 5.00 Very Low Very Low Very Low
Multiple sclerosis 15 5.00 Very Low Very Low Very Low
cva 15 5.00 Very Low Very Low Very Low
cINOD 4 5.00 Very Low Very Low Very Low
rheumatoid arthritis 4 5.00 Very Low Very Low Very Low
Arthritis 2 5.00 Very Low Very Low Very Low
Opioid 2 5.00 Very Low Very Low Very Low
medulla 1 5.00 Very Low Very Low Very Low
Catecholamine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Motor Neuron Diseases 1800 100.00 Very High Very High Very High
Disease Progression 420 99.52 Very High Very High Very High
Neurological Disease 15 99.08 Very High Very High Very High
Chronic Renal Failure 4 99.00 Very High Very High Very High
Disease 706 98.96 Very High Very High Very High
Injury 2 97.40 Very High Very High Very High
Neuroblastoma 50 95.28 Very High Very High Very High
Disorders Of Creatine Metabolism 36 95.24 Very High Very High Very High
Renal Disease 38 94.96 High High
Cardiovascular Disease 17 93.96 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Multivariate correlation analysis demonstrated that the clinical parameters for increased serum cystatin C are a higher stage of chronic kidney disease, older age, use of allopurinol, and lower high density lipoprotein-cholesterol.
Positive_regulation (increased) of cystatin in kidney associated with chronic renal failure
1) Confidence 0.05 Published 2010 Journal Journal of Korean Medical Science Section Abstract Doc Link PMC2800003 Disease Relevance 0.53 Pain Relevance 0
It has been recognized that an increase in serum cystatin C might well reflect changes in renal function or GFR for renal injury in diverse clinical conditions or diseases, including nephropathy associated with type 2 diabetes mellitus (8), hypertensive nephropathy (9), solid organ transplantation (10), and coronary angiopathy (11).
Positive_regulation (increase) of cystatin associated with vascular disease, diabetes mellitus, renal disease, injury, organ transplantation, hypertensive nephropathy and disease
2) Confidence 0.05 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2800003 Disease Relevance 1.36 Pain Relevance 0.04
Direct bisulphite sequencing of CST6 (Cystatin M) 5?
Positive_regulation (sequencing) of Cystatin M
3) Confidence 0.03 Published 2008 Journal Endocrine-Related Cancer Section Body Doc Link PMC2519165 Disease Relevance 0.38 Pain Relevance 0
A repeated measures t-test revealed a modest increase in total cystatin C concentration over time in these healthy controls but no longitudinal change in percent cystatin C levels (data not shown).


Positive_regulation (increase) of cystatin
4) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.06 Pain Relevance 0
These results indicate that CSF cystatin C levels in ALS patients change over time in a clinically-relevant manner and that increasing cystatin C concentration may be associated with slower disease progression.
Positive_regulation (increasing) of cystatin associated with disease progression and motor neuron diseases
5) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.73 Pain Relevance 0
Our findings indicate that cystatin C levels, as determined by ELISA, are increased in the plasma and decreased in the CSF of ALS patients relative to healthy controls.
Positive_regulation (increased) of cystatin in plasma associated with motor neuron diseases
6) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.89 Pain Relevance 0
We verified that cystatin C protein levels are reduced in the CSF of ALS patients and discovered that cystatin C levels are increased in the plasma of ALS patients.
Positive_regulation (increased) of cystatin in plasma associated with motor neuron diseases
7) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 1.36 Pain Relevance 0
We found that plasma cystatin C levels are equivalently elevated in both ALS patients and disease controls relative to healthy controls, indicating that elevated plasma cystatin C is a nonspecific finding associated with neurologic disease states.
Positive_regulation (elevated) of cystatin in plasma associated with disease and motor neuron diseases
8) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 1.10 Pain Relevance 0.03
Furthermore, the observed trend of increasing cystatin C levels in patients with slow rates of clinical deterioration may prove to be useful as an objective biomarker for monitoring drug effects in clinical trials.
Positive_regulation (increasing) of cystatin
9) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.55 Pain Relevance 0
We found that longitudinal cystatin C concentrations were relatively constant in ALS patients as a combined group.
Positive_regulation (constant) of cystatin associated with motor neuron diseases
10) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.86 Pain Relevance 0.03
Finally, the association of high or increasing cystatin C levels with slower disease progression and increased survival time suggests a potential neuroprotective role for this protein in the pathobiology of ALS.


Positive_regulation (increasing) of cystatin associated with motor neuron diseases and disease progression
11) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.82 Pain Relevance 0
These data verify prior results for reduced cystatin C levels in the CSF of ALS patients, identify increased cystatin C levels in the plasma of ALS patients, and reveal correlations between CSF cystatin C levels to both ALS disease progression and patient survival.



Positive_regulation (increased) of cystatin in CSF associated with disease progression and motor neuron diseases
12) Confidence 0.02 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC3000338 Disease Relevance 1.13 Pain Relevance 0
We found that plasma cystatin C levels are equivalently elevated in both ALS patients and disease controls relative to healthy controls, indicating that elevated plasma cystatin C is a nonspecific finding associated with neurologic disease states.
Positive_regulation (elevated) of cystatin in plasma associated with disease and motor neuron diseases
13) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 1.06 Pain Relevance 0
In contrast, slow progressors exhibited a trend of increasing cystatin C levels over time (p?
Positive_regulation (increasing) of cystatin
14) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.25 Pain Relevance 0
Cystatin C levels in ALS patients were significantly elevated in plasma and reduced in CSF compared to healthy controls, but did not differ significantly from neurologic disease controls.
Positive_regulation (elevated) of Cystatin in CSF associated with disease and motor neuron diseases
15) Confidence 0.02 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC3000338 Disease Relevance 1.25 Pain Relevance 0
In contrast, the subgroup of patients with slow or absent clinical disease progression exhibited longitudinal increases in cystatin C concentration, and the subgroup with more typical, continuous clinical deterioration exhibited longitudinal decreases in total cystatin C.
Positive_regulation (increases) of cystatin associated with disease progression
16) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.92 Pain Relevance 0.03
However, the association of higher cystatin C concentrations with longer patient survival and the association of increasing cystatin C levels with slower clinical progression both suggest that extracellular cystatin C may exhibit neuroprotective properties within the context of ALS.
Positive_regulation (increasing) of cystatin associated with motor neuron diseases
17) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.87 Pain Relevance 0
Post-hoc analyses revealed that total and percent cystatin C were significantly increased in both ALS patients and disease controls relative to healthy controls.
Positive_regulation (antly inc) of cystatin associated with disease and motor neuron diseases
18) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.54 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox